Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …

Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …

Introduction: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …

Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal
antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially …

Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …

Gemtuzumab ozogamicin (Mylotarg®) is a conjugate of a monoclonal antibody and
calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid …

Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …

Abstract Gemtuzumab Ozogamicin (GO, CMA-676) is a monoclonal antibody against the
cellular surface antigen CD33 conjugated with the cytotoxic antibiotic calicheamicin. In the …

Despite living in an era of unprecedented progress in the understanding of the genetic and
molecular biology of acute myeloid leukemia (AML), this has not translated into significant …

Gemtuzumab ozogamicin (CMA-676, Mylotarg®), an antibody-targeted chemotherapy
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …